HBM (HKG:2142) has submitted an investigational new drug application to China's National Medical Products Administration for HBM9378, which is intended to treat chronic obstructive pulmonary disease, a Friday bourse filing said.
HBM9378 was developed by the drugmaker in partnership with Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments